

AesculaTech a Finalist to Compete in The Winning Pitch Challenge at Eyecelerator® at AAO 2023


LOS ANGELES, CA, UNITED STATES, October 30, 2023 /EINPresswire.com/ -- AesculaTech, Inc., an emerging leader in innovative ophthalmic technologies, today announced that Niki Bayat, PhD, co-founder and CEO, will participate as a finalist in The Winning Pitch Challenge at Eyecelerator® on November 2nd, during the American Academy of Ophthalmology annual meeting in San Francisco, California.

“The Winning Pitch Challenge has been instrumental in providing a platform for early-stage companies, like

AesculaTech, to showcase their pioneering ideas,” said Dr. Bayat. “We're thrilled to have been selected as a finalist and believe that our groundbreaking medical device, HUMIDIFEYE®, has strong potential to significantly advance the treatment of dry eye disease, as well as other ocular surface conditions.”

Dry eye disease (DED) is one of the most common ocular surface disorders affecting approximately 23 million people in the United States, with 12 million moderate-to-severe DED patients treated with therapies beyond over-the-counter lubricants.^{1,2} HUMIDIFEYE®, a physician-friendly, one-size-fits all device, occludes the tear duct using a breakthrough temperature-responsive hydrogel that adapts to patient anatomy once deployed with the press of a button. In a pilot study, HUMIDIFEYE® demonstrated a rapid improvement in both the signs and symptoms of DED in as early as 2 weeks, with sustained efficacy through 3 months. HUMIDIFEYE® provides a novel and elegant solution to the clinical challenges of traditional punctal plugs by offering excellent comfort, lack of migration or extrusion, decreased chair time, and simplified inventory.

“Our team has put in tremendous effort and dedication, and this accomplishment serves as a testament to our innovative approach and the value we strive to bring to patients with dry eye,”



added Dr. Bayat. “We’re excited to showcase the transformative potential of HUMIDIFEYE® to the audience at Eyecelerator® and the larger eye care community.”

The Winning Pitch Challenge, Eyecelerator® at AAO 2023

Presenter: Niki Bayat, PhD, CEO

Presentation time: Thursday, November 2, 11:00 AM PST

Location: San Francisco Marriott Marquis

About HUMIDIFEYE®

The HUMIDIFEYE® device offers personalized occlusion for tear retention by delivering a proprietary temperature-sensitive punctal hydrogel using a sterile, disposable, one-size-fits all micro-volume autoinjector. Administered as a liquid, the hydrogel adapts to patient anatomy and transitions into a non-degradable flexible solid at body temperature. HUMIDIFEYE® can be easily removed using a prefilled saline syringe designed with an irrigation tip.

In a study of 44 eyes, HUMIDIFEYE® demonstrated an 82% average reduction in DED symptoms as measured by the Ocular Surface Disease Index score, a 73% average reduction in total corneal fluorescein staining, a 197% average increase in basal tears based on Schirmer testing, and an overall improvement in patient quality of life parameters. AesculaTech is moving towards HUMIDIFEYE® market clearance in 2024.

To learn more about HUMIDIFEYE®, visit www.aesculatech.com/meet-humidifeye

About AesculaTech, Inc.

AesculaTech is a private company focused on building better lives through custom chemistry. Founded by University of Southern California researchers in 2016, AesculaTech’s platform technology utilizes a proprietary smart material to develop biomedical and consumer products that are engineered to be adaptable and responsive.

For more information, visit: www.aesculatech.com

References:

1. MarketScope 2021 Dry Eye Products Market Report.
2. Farrand KF, Fridman M, Stillman IÖ, Schaumberg DA. Prevalence of Diagnosed Dry Eye Disease in the United States Among Adults Aged 18 Years and Older. Am J Ophthalmol. 2017;182:90-98.
3. Data on file.

Mary Miller

MH Medical Communications

mary@mhmc.partners

This press release can be viewed online at: <https://www.einpresswire.com/article/665143172>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2023 Newsmatics Inc. All Right Reserved.